Interleukin-2-unresponsive immune defects in good syndrome: Letter to the Editor.
Yang
Otto O
OO
Kelesidis
Theodoros
T
D000998:Antiviral Agents / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology; D018792:Encephalitis, Viral / Q000209:etiology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007156:Immunologic Memory; D007376:Interleukin-2 / Q000627:therapeutic use*; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013945:Thymoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology
D000998:Antiviral Agents; D007155:Immunologic Factors; D007376:Interleukin-2